FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135320265> ?p ?o ?g. }

• W3135320265 endingPage "288" @default.
• W3135320265 startingPage "287" @default.
• W3135320265 abstract "Abstract Background Linaclotide (LIN) is a guanylate cyclase-C agonist approved to treat irritable bowel syndrome with constipation (IBS-C) in adults. Abdominal symptoms are important to patients with IBS-C. In a recent Phase 3b study, LIN significantly improved a composite score of abdominal bloating, pain, and discomfort (Abdominal Score), which was used as the primary endpoint in the study. Aims To evaluate the efficacy of LIN for improving additional efficacy abdominal symptom endpoints in a randomized, double-blind, placebo (PBO)-controlled Phase 3 study of LIN in patients with IBS-C. Methods Adults with IBS-C were randomized to PBO (N=308) or LIN 290 μg (N=306) once daily for 12 weeks. Patients recorded their daily abdominal symptoms, including the individual items of bloating, pain, and discomfort, using an 11-point scale (0–10; 0=none, 10=worst possible). The primary endpoint was the Abdominal Score. Additional efficacy endpoints included 6/12-week abdominal pain and constipation (APC)+1 responder, 6/12-week abdominal bloating responder, 6/12-week abdominal pain responder, and 6/12-week abdominal discomfort responder. For individual symptoms, a responder was a patient who had an improvement from baseline of ≥2 points in the respective endpoint for ≥6 of the 12 weeks. Changes from baseline (CFB) over 12 weeks in abdominal bloating, pain, and discomfort were evaluated using a mixed model with repeated measures framework. Proportions of responders were compared between groups for each responder endpoint using a Cochran-Mantel-Haenszel test. Results 614 patients (mean age, 46.7 years; 81% female; similar baseline abdominal symptoms) were randomized. LIN-treated patients had greater least-squares mean (LSM) CFB in abdominal bloating (LSM difference [95% CI]: –0.889 [–1.249, –0.530], p&lt;0.001), pain (–0.881 [–1.238, –0.524], p&lt;0.001), and discomfort (–0.837 [–1.196, –0.478], p&lt;0.001) compared to PBO-treated patients. There was a greater proportion of LIN-treated vs. PBO-treated patients who were 6/12-week APC+1 (29% vs. 17%; p=0.0003), bloating (40% vs. 24%; p&lt;0.001), pain (42% vs. 25%; p&lt;0.001), and discomfort (42% vs. 26%; p&lt;0.001) responders (Figure). Diarrhea was the most common treatment-emergent adverse event (LIN: 4.6%; PBO: 1.6%). Conclusions LIN significantly improved multiple abdominal symptom and secondary responder endpoints in patients with IBS-C. These results support the effectiveness of LIN for improving a spectrum of abdominal symptoms in IBS-C. Funding Agencies This study was sponsored by Allergan plc, Dublin, Ireland (prior to acquisition by AbbVie Inc.). Writing and editorial assistance were provided to the authors by Brittany Y. Jarrett, PhD, Jane Beck, MA, and Rebecca Fletcher, BA(Hons) of Complete HealthVizion, Inc., Chicago, IL, USA and funded by Allergan plc (prior to acquisition by AbbVie Inc.)." @default.
• W3135320265 created "2021-03-15" @default.
• W3135320265 creator A5006913531 @default.
• W3135320265 creator A5033546631 @default.
• W3135320265 creator A5067924430 @default.
• W3135320265 creator A5084935208 @default.
• W3135320265 creator A5088495636 @default.
• W3135320265 date "2021-03-01" @default.
• W3135320265 modified "2023-10-16" @default.
• W3135320265 title "A237 IMPROVEMENT IN ABDOMINAL SYMPTOMS WITH LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION: RESULTS FROM A PHASE 3B TRIAL" @default.
• W3135320265 doi "https://doi.org/10.1093/jcag/gwab002.235" @default.
• W3135320265 hasPublicationYear "2021" @default.
• W3135320265 type Work @default.
• W3135320265 sameAs 3135320265 @default.
• W3135320265 citedByCount "0" @default.
• W3135320265 crossrefType "journal-article" @default.
• W3135320265 hasAuthorship W3135320265A5006913531 @default.
• W3135320265 hasAuthorship W3135320265A5033546631 @default.
• W3135320265 hasAuthorship W3135320265A5067924430 @default.
• W3135320265 hasAuthorship W3135320265A5084935208 @default.
• W3135320265 hasAuthorship W3135320265A5088495636 @default.
• W3135320265 hasConcept C108797546 @default.
• W3135320265 hasConcept C126322002 @default.
• W3135320265 hasConcept C142724271 @default.
• W3135320265 hasConcept C168563851 @default.
• W3135320265 hasConcept C202953159 @default.
• W3135320265 hasConcept C203092338 @default.
• W3135320265 hasConcept C204787440 @default.
• W3135320265 hasConcept C27081682 @default.
• W3135320265 hasConcept C2776956441 @default.
• W3135320265 hasConcept C2778271842 @default.
• W3135320265 hasConcept C2780955771 @default.
• W3135320265 hasConcept C2781112942 @default.
• W3135320265 hasConcept C71924100 @default.
• W3135320265 hasConcept C90924648 @default.
• W3135320265 hasConceptScore W3135320265C108797546 @default.
• W3135320265 hasConceptScore W3135320265C126322002 @default.
• W3135320265 hasConceptScore W3135320265C142724271 @default.
• W3135320265 hasConceptScore W3135320265C168563851 @default.
• W3135320265 hasConceptScore W3135320265C202953159 @default.
• W3135320265 hasConceptScore W3135320265C203092338 @default.
• W3135320265 hasConceptScore W3135320265C204787440 @default.
• W3135320265 hasConceptScore W3135320265C27081682 @default.
• W3135320265 hasConceptScore W3135320265C2776956441 @default.
• W3135320265 hasConceptScore W3135320265C2778271842 @default.
• W3135320265 hasConceptScore W3135320265C2780955771 @default.
• W3135320265 hasConceptScore W3135320265C2781112942 @default.
• W3135320265 hasConceptScore W3135320265C71924100 @default.
• W3135320265 hasConceptScore W3135320265C90924648 @default.
• W3135320265 hasIssue "Supplement_1" @default.
• W3135320265 hasLocation W31353202651 @default.
• W3135320265 hasOpenAccess W3135320265 @default.
• W3135320265 hasPrimaryLocation W31353202651 @default.
• W3135320265 hasRelatedWork W102111670 @default.
• W3135320265 hasRelatedWork W1544394016 @default.
• W3135320265 hasRelatedWork W2057226727 @default.
• W3135320265 hasRelatedWork W2086642698 @default.
• W3135320265 hasRelatedWork W2098294301 @default.
• W3135320265 hasRelatedWork W2132145612 @default.
• W3135320265 hasRelatedWork W2147533789 @default.
• W3135320265 hasRelatedWork W3135320265 @default.
• W3135320265 hasRelatedWork W4237612285 @default.
• W3135320265 hasRelatedWork W4243345359 @default.
• W3135320265 hasVolume "4" @default.
• W3135320265 isParatext "false" @default.
• W3135320265 isRetracted "false" @default.
• W3135320265 magId "3135320265" @default.
• W3135320265 workType "article" @default.